Bastyr to undertake echinacea-respiratory tract infection study funded by Madaus AG.
This article was originally published in The Tan Sheet
Executive Summary
BASTYR ECHINACEA AND RESPIRATORY TRACT INFECTIONS $385,000 STUDY is being funded by Cologne, Germany-based company Madaus AG. The 16-month, double-blind, placebo-controlled study will examine the effectiveness of Echinacea purpurea (purple coneflower) in mitigating the frequency and severity of respiratory tract infections as a potential alternative to antibiotics.